• Sign up to our Free Newsletter
  • Contact Us
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: December 2022

Editor's Choice

Microbiome Drug Development: 2022 in Review

December 30, 2022 Luis Gosálbez

Leveraging a year of important research updates, funding rounds, and academic papers, this report compiles the most significant industry news pertaining to microbiome drug development in 2022. It finds that the regulatory approval of three […]

Editor's Choice

Exclusive Interview with Ken Blount, VP Microbiome Research at Ferring Pharmaceuticals

December 22, 2022 Microbiome Times
Finance

Biomica Raises $20 Million to Advance its Pipeline of Microbiome-based Therapeutics

December 22, 2022 Microbiome Times

Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to […]

Pharma & Human Health

Atomic structure of a staphylococcal bacteriophage using cryo-electron microscopy

December 21, 2022 Microbiome Times

Cryo-electron microscopy by University of Alabama at Birmingham researchers has exposed the structure of a bacterial virus with unprecedented detail. This is the first structure of a virus able to infect Staphylococcus epidermidis, and high-resolution […]

Finance

Beiersdorf acquires S-Biomedic and strengthens expertise in the field of acne treatment

December 16, 2022 Microbiome Times

Beiersdorf AG announced today that it has acquired a majority stake in S-Biomedic NV, Belgium, a life-science company and frontrunner in the field of skin microbiome research. Beiersdorf recognized the potential of the skin microbiome […]

Finance

A Biosolutions Juggernaut: Novozymes and Chr. Hansen to merge into one corporation

December 13, 2022 Microbiome Times

On December 12th, Novozymes and Chr. Hansen, two of the world’s leading biosolutions corporations, entered into an agreement to merge into a novel company. Prompted by global megatrends, including climate considerations, food system security, and […]

Editor's Choice

FDA Approves First Fecal Microbiota Product

December 1, 2022 Microbiome Times

Today, the U.S. Food and Drug Administration approved Rebyota, the first fecal microbiota product approved by the agency. Rebyota is approved for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years […]

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • Microbiome drug development: Analysis of the historical pipeline reveals promising areas and bottlenecks
    May 25, 2023
  • DNA Genotek enables development of microbiome-based clinical applications with OMNIgene™•GUT Dx – the first and only FDA-authorized fecal self-collection device
    May 10, 2023
  • Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™
    April 27, 2023
  • Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
    April 25, 2023
  • Researchers create virus-resistant, safely restrained E. coli
    April 10, 2023
sign up

Sign up to the Microbiome Times newsletter